Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Tests a smart ring that tracks health data in people with MDS

Checks whether adults with myelodysplastic syndromes can wear an OURA ring for 3 months.

Plain-language title generated from the registry record
Registry title: OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study

Key facts

Where
Toronto, CanadaSee the site

Where in Canada

  • Sunnybrook Health Sciences Research CentreToronto, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Sunnybrook Health Sciences Centre
Trial code
NCT06270771
Record updated
8 July 2025
Original description
A prospective, single center, single arm phase 2 cohort feasibility study of the OURA ring in adult MDS patients. Patients with MDS will wear the OURA ring and upload biometrics weekly. Quality of life measures will be clinically evaluated and correlated with biometrics. We hypothesize that it will be feasible for MDS patients to wear the OURA ring 70% of the time for 3 months.Read full original descriptionShow less

OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study

A prospective, single center, single arm phase 2 cohort feasibility study of the OURA ring in adult MDS patients. Patients with MDS will wear the OURA ring and upload biometrics weekly. Quality of life measures will be clinically evaluated and correlated with biometrics. We hypothesize that it will be feasible for MDS patients to wear the OURA ring 70% of the time for 3 months.

Inclusion: Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Male or female, aged 18 or older; Able to read, write and speak English or French (non-English or French speaking patients may participate if appropriate translation is used); Diagnosed with Myelodysplastic Syndrome using WHO 2022 criteria (12) all risk groups; Ability to wear the OURA ring and operate the associated smart-phone app, and willing to adhere to the study regimen.

Exclusion: Cognitive or physical impairment preventing the usage or utilization of the OURA ring and smart phone; Performance status ECOG > 3.

ClinicalTrials.gov NCT06270771